Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

信銘生命科技集團有限公司
Aceso Life Science Group Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00474)

VOLUNTARY ANNOUNCEMENT
FULL REPAYMENT OF OUTSTANDING LOAN OF A COMMERCIAL BANK IN HONG KONG

This announcement is made by Aceso Life Science Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

Reference is made to the announcement of the Company dated 23 April 2025 (the "**Announcement**") in relation to the receipt by the Company of a demand letter from a commercial bank in Hong Kong on 23 April 2025, demanding the payment of the Indebtedness in the sum of approximately HK$352 million. Unless otherwise stated, capitalized terms herein shall have the same meanings as those defined in the Announcement.

The Company is pleased to announce that up to the date of this announcement, the Company has already repaid all outstanding Indebtedness in full.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Aceso Life Science Group Limited
Zhiliang Ou
Executive Director

Hong Kong, 28 October 2025

As at the date of this announcement, the board of directors of the Company comprises two executive directors, namely Dr. Zhiliang Ou, J. P. (Australia) and Mr. Fok Chi Tak; one non-executive director, namely Ms. Jiang Yang; and three independent non-executive directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.